🇺🇸 FDA
Pipeline program

UGN-103 (Mitomycin)

BL013

Phase 3 small_molecule active

Quick answer

UGN-103 (Mitomycin) for Nonmuscle Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Nonmuscle Invasive Bladder Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials